At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of PsA classified by CASPAR criteria
- ✓Rheumatoid factor and anti-CCP antibodies negative
- ✓Active plaque psoriasis with at least one psoriatic plaque ≥2 cm diameter, or nail changes consistent with psoriasis, or documented history of plaque psoriasis
- ✓Inadequate control of symptoms with NSAIDs
- ✕Pregnant or nursing women
- ✕Evidence of ongoing infectious or malignant process
- ✕Previous exposure to any biologic drug for PsA or psoriasis
- ✕Taking high potency opioid analgesics
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
In Brief
A Phase 3 clinical trial evaluating Secukinumab and Adalimumab for Psoriatic Arthritis. Completed, enrolled 853 participants across 156 sites in 26 countries.
Detailed Summary
This was a randomized, double-blind, active controlled, multicenter, parallel-group study evaluating secukinumab monotherapy and adalimumab monotherapy in approximately 850 patients with active psoriatic arthritis (PsA) who are naïve to biologic therapy and are intolerant or having inadequate response to conventional disease modifying anti-rheumatic drugs (also known as non-biologic DMARDs).
Study Details
Timeline
Interventions
Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio